Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

After having hosted Intellia Therapeutics ’ CEO John Leonard at the firm’s healthcare conference, JPMorgan said management “shed light” on the thinking behind the strategi ...

Intellia Therapeutics Inc (NTLA) stock saw a decline, ending the day at $10.2 which represents a decrease of $-1.82 or -15.14% from the prior close of $12.02. The stock opened at $11.24 and touched a ...

周一，Oppenheimer调整了对Intellia Therapeutics (NASDAQ:NTLA)股票的展望，将公司的目标价从之前的60.00美元下调至40.00美元。尽管目标价下调，但该公司仍维持对这家生物技术公司股票的"优于大市"评级。这一决定是在Intellia Therapeutics宣布战略调整和裁员以延长财务周期后做出的。

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

北京时间2025年01月14日02时29分，再生元制药公司（REGN.us）股票出现异动，股价大幅上涨0.50%。截至发稿，该股报700.35美元/股，成交量77.6291万股， 换手率 0.71%，振幅4.84%。

The injured cows have been taken to the Chamarajpet veterinary hospital for treatment after their udders were severed by unidentified wrongdoers.